Leukemia

Article	Citations
Retraction Note: SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide	2256
STING mediates increased self-renewal and lineage skewing in DNMT3A-mutated hematopoietic stem/progenitor cells	1984
Correction: Mutant SETBP1 enhances NRAS-driven MAPK pathway activation to promote aggressive leukemia	176
CD38 in the pathobiology of cutaneous T-cell lymphoma and the potential for combination therapeutic intervention	169
Co-targeting of the thymic stromal lymphopoietin receptor to decrease immunotherapeutic resistance in CRLF2-rearranged Ph-like and Down syndrome acute lymphoblastic leukemia	154
Correspondence to: “Combination therapies with ponatinib and asciminib in a preclinical model of chronic myeloid leukemia blast crisis with compound mutations”, Curik N et al. Leukemia. 2024; 38: 1415	140
TLE4 is a repressor of the oncogenic activity of TLX3 in T-cell acute lymphoblastic leukemia	135
Nelarabine in T-cell acute lymphoblastic leukemia: intracellular metabolism and molecular mode-of-action	122
Rheumatoid arthritis and the risk of hematologic malignancies: a nationwide cohort study	122
FBXO21 mediated degradation of p85α regulates proliferation and survival of acute myeloid leukemia	120
Targeting a mitochondrial E3 ubiquitin ligase complex to overcome AML cell-intrinsic Venetoclax resistance	120
mTOR inhibition amplifies the anti-lymphoma effect of PI3Kβ/δ blockage in diffuse large B-cell lymphoma	117
UBTF tandem duplications define a distinct subtype of adult de novo acute myeloid leukemia	99
Genomic abnormalities of TP53 define distinct risk groups of paediatric B-cell non-Hodgkin lymphoma	98
Patterns and variations of copy number alterations in acute myeloid leukemia: insights from the LeukAtlas database	93
Inhibition of NOTCH4 sensitizes FLT3/ITD acute myeloid leukemia cells to FLT3 tyrosine kinase inhibition	91
Differential prognostic impact of IDH1 and IDH2 mutations in chronic myelomonocytic leukemia	90
Space exploration and cancer: the risks of deeper space adventures	88
Changing causes of death in persons with haematological cancers 1975–2016	88
Hairy cell leukemia variant and WHO classification correspondence Re: 5th edition WHO classification haematolymphoid tumors: lymphoid neoplasms	84
Measurable residual disease in haematological and solid cancers	80
Adding eltrombopag to intensive immunosuppressive therapy for severe aplastic anaemia may help adult patients achieve outcomes similar to paediatric patients	80
Dimethyl fumarate ameliorates chronic graft-versus-host disease by inhibiting Tfh differentiation via Nrf2	78
“Blasts” in myeloid neoplasms – how do we define blasts and how do we incorporate them into diagnostic schema moving forward?	75
CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results	75

Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures	73
Characterization of leukemia progression in the Cbfb-MYH11 knockin mice by single cell RNA sequencing	73
RUNX1 mutations mitigate quiescence to promote transformation of hematopoietic progenitors in Fanconi anemia	71
Does older age justify chlorambucil control arms for chronic lymphocytic leukemia clinical trials: a SEER-Medicare analysis	69
Inserting EF1α-driven CD7-specific CAR at CD7 locus reduces fratricide and enhances tumor rejection	68
Identification of therapeutic targets of the hijacked super-enhancer complex in EVI1-rearranged leukemia	68
Somatic TP53 single nucleotide variants, indels and copy number alterations in chronic myelomonocytic leukemia (CMML)	68
External validation of the predictive scoring systems for molecular responses in chronic myeloid leukaemia receiving initial imatinib-therapy	67
Significance of chromosome 2p gain in ibrutinib-treated chronic lymphocytic leukemia patients	66
Emil J. Freireich: Legend in Cancer Research (March 16, 1927 to February 1, 2021)	65
JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis	65
What role for somatic mutations in systemic inflammatory and autoimmune diseases associated with myelodysplastic neoplasms and chronic myelomonocytic leukemias?	63
Culture expansion of CAR T cells results in aberrant DNA methylation that is associated with adverse clinical outcome	63
Fc-fused IL-7 mobilizes long-term HSCs in a pro-B cell-dependent manner and synergizes with G-CSF and AMD3100	62
Myelodysplastic neoplasm-associated U2AF1 mutations induce host defense defects by compromising neutrophil chemotaxis	61
Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: reevaluation of the defining characteristics in a registry-based cohort	60
Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial	59
Perspectives on acute myeloid leukemia diagnosis: a comparative analysis of the latest World Health Organization and the International Consensus Classifications	59
Why are haematopoietic stem cells in the bone marrow: ontology recapitulates phylogeny	59
Comparison between measurable residual disease relapse and morphologic relapse in acute myeloid leukemia and high-grade myeloid neoplasms	58
MCL1 regulates AML cells metabolism via direct interaction with HK2. Metabolic signature at onset predicts overall survival in AMLs’ patients	58
The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial	56
COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia	54
CD7 targeted “off-the-shelf” CAR-T demonstrates robust in vivo expansion and high efficacy in the treatment of patients with relapsed and refractory T cell malignancies	53
An “off-the-shelf” CD2 universal CAR-T therapy for T-cell malignancies	53
Correction: Frequent HLA-DR loss on hematopoietic stem progenitor cells in patients with cyclosporine-dependent aplastic anemia carrying HLA-DR15	53
Improved survival in multiple myeloma during the 2005–2009 and 2010–2014 periods	52
Nuclear war and physicians’ social responsibility	51
Increasing recognition and emerging therapies argue for dedicated clinical trials in chronic myelomonocytic leukemia	49
Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update	48
Prevalence of UBA1 mutations in MDS/CMML patients with systemic inflammatory and auto-immune disease	46
The P2X4 purinergic receptor has emerged as a potent regulator of hematopoietic stem/progenitor cell mobilization and homing—a novel view of P2X4 and P2X7 receptor interaction in orchestrating stem ce	46
PDP1 is a key metabolic gatekeeper and modulator of drug resistance in FLT3-ITD-positive acute myeloid leukemia	46
COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey	46
Mutations in DEAD/H-box helicase 11 correlate with increased relapse risk in adults with acute myeloid leukaemia with normal cytogenetics	45
3-Ketodihydrosphingosine reductase maintains ER homeostasis and unfolded protein response in leukemia	45
Tumor heterogeneity and immune-evasive T follicular cell lymphoma phenotypes at single-cell resolution	45
Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study	44
Chronic lymphocytic leukemia patient-derived xenografts recapitulate clonal evolution to Richter transformation	44
Genomic DNA-based measurable residual disease monitoring in pediatric acute myeloid leukemia: unselected consecutive cohort study	44
DELE1 haploinsufficiency causes resistance to mitochondrial stress-induced apoptosis in monosomy 5/del(5q) AML	44
Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis	43
Correction: Genomic analysis of cellular hierarchy in acute myeloid leukemia using ultrasensitive LC-FACSeq	43
Analysis of autophagy in DLBCL reveals subtype-specific differences and the preferential targeting of ULK1 inhibition in GCB-DLBCL provides a rationale as a new therapeutic approach	43
OST-01, a natural product from Baccharis coridifolia, targets c-Myc-dependent ribogenesis in acute myeloid leukemia	43
Correction to: TAL1 hijacks MYCN enhancer that induces MYCN expression and dependence on mevalonate pathway in T-cell acute lymphoblastic leukemia	42
DNA-TG and risk of sinusoidal obstruction syndrome in childhood acute lymphoblastic leukemia	42
Publisher Correction: Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age	41
Enhanced Risk Stratification for Children and Young Adults with B-Cell Acute Lymphoblastic Leukemia: A Children’s Oncology Group Report	41
Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohorts	41

Circulating cytokines present in multiple myeloma patients inhibit the osteoblastic differentiation of adipose stem cells	41
Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study	40
Modeling clonal hematopoiesis in umbilical cord blood cells by CRISPR/Cas9	39
The evolution of preclinical models for myelodysplastic neoplasms	39
The IL-3, IL-5, and GM-CSF common receptor beta chain mediates oncogenic activity of FLT3-ITD-positive AML	39
Functional precision oncology for follicular lymphoma with patient-derived xenograft in avian embryos	39
Publisher Correction: Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide—an International Collaborative Study	39
Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial	39
Clonal medicine targeting DNA damage response eradicates leukemia	39
Phase 2 study using low dose cytarabine for adult patients with newly diagnosed Langerhans cell histiocytosis	39
Correction: Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib – interim results from the DAstop2 trial	38
Genome-wide DNA methylation-analysis of blastic plasmacytoid dendritic cell neoplasm identifies distinct molecular features	38
Inflammation and infection in plasma cell disorders: how pathogens shape the fate of patients	38
Nucleolin as activator of TCF7L2 in human hematopoietic stem/progenitor cells	38
Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the DRST and GREM registries	37
Treatment and survival for patients with localized primary ocular adnexal extranodal marginal zone lymphoma	37
Correction to: Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation	37
Hal E. Broxmeyer PhD: Experimental haematologist and umbilical cord blood cell transplant pioneer (27 November, 1944–8 December, 2021)	37
The potential of cell-free DNA to reveal the molecular profiles of Langerhans cell histiocytosis and Erdheim–Chester disease in adults	36
Physician and patient perceptions on randomization of treatment intensity for unfit adults with acute myeloid leukemia and other high-grade myeloid neoplasm	36
Clonal hematopoiesis and its impact on the aging osteo-hematopoietic niche	36
Correction: Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer	36
A simple algorithm with one flow cytometric MRD measurement identifies more than 40% of children with ALL who can be cured with low-intensity therapy. The ALL-MB 2008 trial results	35
Early relapse is an adverse prognostic marker in systemic immunoglobulin light chain (AL) Amyloidosis	35
Co-targeting leukemia-initiating cells and leukemia bulk leads to disease eradication	35
Publisher Correction: SIRT7: an influence factor in healthy aging and the development of age-dependent myeloid stem-cell disorders	35
The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma—a randomized, open-label phase III trial of the European mantle cell lymp	35
Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes	34
The landscape of RNA-chromatin interaction reveals small non-coding RNAs as essential mediators of leukemia maintenance	34
Immunoglobulin superfamily member 8 maintains myeloid leukemia stem cells through inhibition of β-catenin degradation	34
Liquid biopsy: an evolving paradigm for the biological characterisation of plasma cell disorders	34
A positive feedback loop regulation between NOTCH1 and USP11 in T-cell leukemia	33
Single base substitution and insertion/deletion mutational signatures in adult core binding factor acute myeloid leukemia	32
Targeting CERS6-AS1/FGFR1 axis as synthetic vulnerability to constrain stromal cells supported proliferation in Mantle cell lymphoma	32
Point-of-care BCR::ABL1 transcript monitoring using capillary dried blood in chronic myeloid leukemia patients	32
An MDM2 degrader for treatment of acute leukemias	32
IL-10R inhibition reprograms tumor-associated macrophages and reverses drug resistance in multiple myeloma	31
Genome-wide CRISPR/Cas9 library screening identified OGDH as a regulator of disease progress and resistance to decitabine in myelodysplastic neoplasm by reprogramming glutamine metabolism	31
Combining LSD1 and JAK-STAT inhibition targets Down syndrome-associated myeloid leukemia at its core	31
Cohesin mutations in acute myeloid leukemia	31
Mutant IL7R collaborates with MYC to induce T-cell acute lymphoblastic leukemia	30
Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial	30
Pediatric T-ALL type-1 and type-2 relapses develop along distinct pathways of clonal evolution	30
Are measurable residual disease results after consolidation therapy useful in children with acute lymphoblastic leukemia?	30
Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis	30
Comparative small molecule screening of primary human acute leukemias, engineered human leukemia and leukemia cell lines	29
Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD, nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic leukemia and lymphoma	29
The epigenetic state of the cell of origin defines mechanisms of leukemogenesis	29
Characterisation and prognostic impact Of ZRSR2 mutations in myeloid neoplasms	29
Genome-wide CRISPR screen identifies MAD2L1BP and ANAPC15 as targets for brentuximab vedotin sensitivity in CD30+ peripheral T-cell lymphoma	29
Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia	29
A prognostic survival nomogram for persons with extra-nodal natural killer-/T-cell lymphoma	29
Characterization of myeloproliferative neoplasms based on genetics only and prognostication of transformation to blast phase	29
A DNA methylation database of human and mouse hematological malignancy cell lines	28
A senescence stress secretome is a hallmark of therapy-related myeloid neoplasm stromal tissue occurring soon after cytotoxic exposure	28
Dimethyl fumarate and extracorporeal photopheresis combination-therapy synergize in inducing specific cell death and long-term remission in cutaneous T cell lymphoma	28
Antibody blockade of the PSGL-1 immune checkpoint enhances T-cell responses to B-cell lymphoma	28
Anagrelide and idarubicin combination induces GSDME-mediated pyroptosis as a potential therapy for high-PDE3A acute myeloid leukemia	28
A phase II trial of ipilimumab, nivolumab, or ipilimumab and nivolumab with or without azacitidine in relapsed or refractory myelodysplastic neoplasms	28
CD36 cell surface expression as a surrogate marker to identify ABL/JAK-class kinase fusions in pediatric BCP-ALL	28
MSI2 mediates WNT/β-Catenin pathway function in hematopoietic stem cells	28
Multi-hit TET2 mutations as a differential molecular signature of oligomonocytic and overt chronic myelomonocytic leukemia	27
Neoantigen reactive T cells correlate with the low mutational burden in hematological malignancies	27
Association of hematologic response and assay sensitivity on the prognostic impact of measurable residual disease in acute myeloid leukemia: a systematic review and meta-analysis	27
Correction: Translatome proteomics identifies autophagy as a resistance mechanism to on-target FLT3 inhibitors in acute myeloid leukemia	27
DDX41 coordinates RNA splicing and transcriptional elongation to prevent DNA replication stress in hematopoietic cells	27
Correction to: Functional classification of RUNX1 variants in familial platelet disorder with associated myeloid malignancies	27
Differences in classification schemata for myelodysplastic/myeloproliferative overlap neoplasms	26
Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/F	26
Invasive fungal diseases impact on outcome of childhood ALL – an analysis of the international trial AIEOP-BFM ALL 2009	26
Splenomegaly (SPML) in polycythemia vera (PV): its clinical significance and its relation to symptoms, post-polycythemic myelofibrosis (PPMF) and survival	26
Effect of ECOG performance status on outcomes in patients with acute myeloid leukemia and other high-grade myeloid neoplasms	26
Classification of rare pediatric myeloid neoplasia—Quo vadis?	25
The 5th edition of the WHO classification of haematolymphoid tumors: comments from the Groupe Francophone de Cytogénétique Hématologique (GFCH)	25
Comparison of the revised 4th (2016) and 5th (2022) editions of the World Health Organization classification of myelodysplastic neoplasms	25
Novel causative variants of VEXAS in UBA1 detected through whole genome transcriptome sequencing in a large cohort of hematological malignancies	25
Correction: Continuous Indexing of Fibrosis (CIF): improving the assessment and classification of MPN patients	25
KDM6 demethylases integrate DNA repair gene regulation and loss of KDM6A sensitizes human acute myeloid leukemia to PARP and BCL2 inhibition	25
Clonal hematopoiesis is associated with hematological toxicity during lenalidomide-based therapy for MCL	25
Daniel Catovsky (1937–2022)	25

MCL1 as a therapeutic vulnerability in Burkitt lymphoma	25
Venetoclax consolidation in high-risk CLL treated with ibrutinib for ≥1 year achieves a high rate of undetectable MRD	24
Correction to: Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113AML patients	24
Correction: Generation and characterization of a novel hematopoietic progenitor cell line with DC differentiation potential	24
MiRNA-363-3p/DUSP10/JNK axis mediates chemoresistance by enhancing DNA damage repair in diffuse large B-cell lymphoma	24
A comparison of the International Consensus and 5th World Health Organization classifications of mature B-cell lymphomas	24
Kinase-independent role of mTOR and on-/off-target effects of an mTOR kinase inhibitor	24
Quantifying measurable residual disease correctly	24
What is the impact of failing to achieve TKI therapy milestones in chronic myeloid leukemia	24
A key role of the WEE1-CDK1 axis in mediating TKI-therapy resistance in FLT3-ITD positive acute myeloid leukemia patients	24
Outcomes of frailty subgroups of older adults (age ≥ 70) treated with teclistamab: an International Myeloma Foundation immunotherapy database real-world analysis	24
In vivo kinetics of early, non-random methylome and transcriptome changes induced by DNA-hypomethylating treatment in primary AML blasts	24
T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments	24
PU.1 and MYC transcriptional network defines synergistic drug responses to KIT and LSD1 inhibition in acute myeloid leukemia	24
KDM4B modulates autocrine IL6 in erythroblasts to prevent ineffective erythropoiesis	24
Can PROTACs cure Leukemia?	24
Multi-omic analysis of chronic myelomonocytic leukemia monocytes reveals metabolic and immune dysregulation leading to altered macrophage polarization	23
Genetic and transcriptomic analyses of diffuse large B-cell lymphoma patients with poor outcomes within two years of diagnosis	23
Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study	23
Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation	23
A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML	23
Exploiting the fibroblast growth factor receptor-1 vulnerability to therapeutically restrict the MYC-EZH2-CDKN1C axis-driven proliferation in Mantle cell lymphoma	23
Who wins the combat, CAR or TCR?	23
BCR::ABL1 Proteolysis-targeting chimeras (PROTACs): The new frontier in the treatment of Ph+ leukemias?	23
Hematopoiesis and innate immunity: an inseparable couple for good and bad times, bound together by an hormetic relationship	23
Panel-based RNA fusion sequencing improves diagnostics of pediatric acute myeloid leukemia	23
Evolution of T-cell fitness through AML progression: enhanced bispecific T-cell engager-mediated function of bone marrow T cells at remission compared to initial diagnosis and relapse	22
Germline CHEK2 mutations in patients with myeloid neoplasms	22
Genome-wide trans-ethnic meta-analysis identifies novel susceptibility loci for childhood acute lymphoblastic leukemia	22
Small-molecule inhibitor targeting the Hsp70-Bim protein–protein interaction in CML cells overcomes BCR-ABL-independent TKI resistance	22
Real-time genomic characterization of pediatric acute leukemia using adaptive sampling	22
High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance	22
Analysis and therapeutic targeting of the EP300 and CREBBP acetyltransferases in anaplastic large cell lymphoma and Hodgkin lymphoma	22
ACOX1-mediated peroxisomal fatty acid oxidation contributes to metabolic reprogramming and survival in chronic lymphocytic leukemia	22
Diverse mechanisms of leukemogenesis associated with PAX5 germline mutation	21
Deep learning detects acute myeloid leukemia and predicts NPM1 mutation status from bone marrow smears	21
A unique role of p53 haploinsufficiency or loss in the development of acute myeloid leukemia with FLT3-ITD mutation	21
Real life evaluation of AlphaMissense predictions in hematological malignancies	21
Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community	21
REXO5 promotes genomic integrity through regulating R-loop using its exonuclease activity	21
Catch me if you can: how AML and its niche escape immunotherapy	21
Osteocyte-derived exosomes confer multiple myeloma resistance to chemotherapy through acquisition of cancer stem cell-like features	20
SF3B1 mutated MDS: Blast count, genetic co-abnormalities and their impact on classification and prognosis	20
Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome	20
Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients	20
Context-dependent role of trisomy 6 in myelodysplastic neoplasms and acute myeloid leukemia: a multi-omics analysis	20
Targeting the NOTCH1-MYC-CD44 axis in leukemia-initiating cells in T-ALL	20
Combination p53 activation and BCL-xL/BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia	20
Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial	20
Recommendations from the AML molecular MRD expert advisory board	20
Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9	20
ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation?	20
Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML	20
Nucleic acid therapeutics as differentiation agents for myeloid leukemias	20
The complex karyotype in hematological malignancies: a comprehensive overview by the Francophone Group of Hematological Cytogenetics (GFCH)	20
Inability to phosphorylate Y88 of p27Kip1 enforces reduced p27 protein levels and accelerates leukemia progression	20
Dual inhibition of CHK1/FLT3 enhances cytotoxicity and overcomes adaptive and acquired resistance in FLT3-ITD acute myeloid leukemia	20
SF3B1 mutations in AML are strongly associated with MECOM rearrangements and may be indicative of an MDS pre-phase	20
The KMT2A recombinome of acute leukemias in 2023	20
Malignant JAK-signaling: at the interface of inflammation and malignant transformation	20
Focal disruption of DNA methylation dynamics at enhancers in IDH-mutant AML cells	20
Impact of treatment for adolescent and young adults with essential thrombocythemia and polycythemia vera	19
Urine-free response criteria predict progression-free survival in multiple myeloma: a post hoc analysis of BMT CTN 0702	19
Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial	19
Real-world analysis of teclistamab in 123 RRMM patients from Germany	19
Loss of Socs2 improves molecular responses to IFNα in a mouse model of myeloproliferative neoplasms driven by JAK2-V617F	19
Comparison of subcutaneous injection versus intravenous infusion of cytarabine for induction therapy in adult acute myeloid leukemia	19
Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG)	19
Senescence profiling of monoclonal gammopathies reveals paracrine senescence as a crucial defense against disease progression	19
Essential role of Dhx16-mediated ribosome assembly in maintenance of hematopoietic stem cells	19
Single-cell analysis reveals the chemotherapy-induced cellular reprogramming and novel therapeutic targets in relapsed/refractory acute myeloid leukemia	19
Anti-CD19 CAR-T cell therapy for acquired hemophilia A	19
Comparison of recognition of symptom burden in MPN between patient- and physician-reported assessment – an intraindividual analysis by the German Study Group for MPN (GSG-MPN)	19
Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma	19
Venetoclax in combination with hypomethylating agents in chronic myelomonocytic leukemia: a propensity score matched multicenter cohort study	19
Phase 3 study of gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia	19
Modeling GATA2 deficiency in mice: the R396Q mutation disrupts normal hematopoiesis	18
Targeting ABCD1-ACOX1-MET/IGF1R axis suppresses multiple myeloma	18
Correction: Perspectives of current understanding and therapeutics of Diamond-Blackfan anemia	18
Targeting leukemia-specific dependence on the de novo purine synthesis pathway	18
Effective eradication of acute myeloid leukemia stem cells with FLT3-directed antibody-drug conjugates	18
Impaired binding affinity of YTHDC1 with METTL3/METTL14 results in R-loop accumulation in myelodysplastic neoplasms with DDX41 mutation	18
Dual intron-targeted CRISPR-Cas9-mediated disruption of the AML RUNX1-RUNX1T1 fusion gene effectively inhibits proliferation and decreases tumor volume in vitro and in vivo	18
Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study	18
Publisher Correction: Rolf Neth (October 6, 1926–March 17, 2020)	18
Perspectives of current understanding and therapeutics of Diamond-Blackfan anemia	18
miR-196b-Oct1/2 axis regulates DNMT3A-mutant AML pathogenesis	17
Eutos long-term survival score discriminates different Sokal score categories in chronic myeloid leukemia patients, showing better survival prediction. Analysis of the GIMEMA CML observational study	17
Myeloid-derived suppressor cell subtypes differentially influence T-cell function, T-helper subset differentiation, and clinical course in CLL	17
Characteristics of patients with myelodysplastic neoplasm and spliceosome mutations	17
Correction to: The long non-coding RNA CRNDE regulates growth of multiple myeloma cells via an effect on IL6 signaling	17
Gene expression derived from alternative promoters improves prognostic stratification in multiple myeloma	17
Infection-related pathway activation and vulnerability to arsenic trioxide in acute promyelocytic leukemia with TTMV::RARA	17
Tip60 activates Hoxa9 and Meis1 expression through acetylation of H2A.Z, promoting MLL-AF10 and MLL-ENL acute myeloid leukemia	17
Cell fate determinant Llgl1 is required for propagation of acute myeloid leukemia	17